Gadoksetovaya acid

When ATH:
V08CA10

Pharmacological action

Contrast paramagnetic ion diagnostic tool, a stable chelate Gd-EOB-DTPA (Gadolinium-diethylene etoksibenzid -pentaacetic acid). Thanks paramagnetic properties provides increased image contrast during MRI and facilitates visualization of abnormal structures in the investigated organs and tissues.

Pharmacokinetics

After the on / in the active substance diffuses rapidly into the extracellular space. Through 7 days after administration in rats and dogs is determined less 1% dose. Highest concentrations were found in the kidney and liver.

Active substance penetrates through the BBB and to a small extent crosses the placental barrier.

Displayed equally kidney and gall. T1 / 2 is about 1 no.

Total plasma clearance is about 250 ml / min, renal clearance - about 120 ml / min.

In patients with severely impaired renal function T1 / 2 increases slightly, when severe renal insufficiency (provevdeniya hemodialysis if necessary) T1 / 2 significantly increases.

Testimony

To improve the contrast during MRI to detect local lesions in the liver in adults

Contraindications

Hypersensitivity to gadoksetovoy acid.

Pregnancy and lactation

If necessary, use during pregnancy should be carefully weigh the potential benefits of therapy to the mother and the potential risk to the fetus.

Unknown, whether the active substance is released in breast milk in humans.

Cautions

The risk of severe allergic reactions, up to anaphylactic shock, increased when specifying a history of allergic reactions to any allergens, especially to the older contrast media; bronchial asthma and other allergic diseases. Most of these reactions occur within 30 minutes after administration, but possible delayed effects (from several hours to days). After the introduction of gadoksetovoy acid are also possible manifestations of idiosyncrasy with cardiovascular, respiratory and skin reactions.

Considering this, after the procedure recommended monitor the patient for some time.

In case of hypersensitivity reactions administration of contrast agents should be stopped immediately, and conduct emergency treatment.

Do not allow the / m, tk. the ability of local intolerance reactions, including tissue necrosis.

Caution is required when used in patients with severe cardiovascular diseases, tk. Clinical data for these patients are limited.

In clinical studies, in some cases, there was an increase in the QT interval tranzitoronoe without any adverse reactions.

There is evidence of the development of nephrogenic systemic fibrosis after application of contrast agents, containing gadolinium, in patients with severe renal impairment and in patients with acute renal insufficiency of any severity due to the hepatorenal syndrome or in the perioperative liver transplantation during. Considering this, renal impairment gadoksetovuyu acid should be used only after a thorough examination and evaluation of the ratio of benefits and risks for the patient.